Rigel Pharmaceuticals (FRA:RI2) Moat Score: 3/10 (As of Jul. 01, 2026)


FRA:RI2 Rigel Pharmaceuticals Inc FRA:RI2
76 GF Score
Price €33.59
GF Value €24.33
! 7 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals Moat Score?

Rigel Pharmaceuticals FRA:RI2 +0.24% 76 Moat Score is 3 as of Jul. 01, 2026. GuruFocus rates FRA:RI2 with a GF Score™ of 76/100 and a GF Value™ of €24.33. The stock has 7 warning signs investors should review. Among 1,401 Biotechnology companies, Rigel Pharmaceuticals ranks better than 75.52% on this metric.

Rigel Pharmaceuticals has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Rigel Pharmaceuticals has No Moat: Rigel Pharmaceuticals Inc has very weak competitive advantages. While it has some intellectual property, it lacks market leadership, strong brand strength, and significant regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Rigel Pharmaceuticals might have No Moat - Very weak/transient advantages.

Rigel Pharmaceuticals  (FRA:RI2) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Rigel Pharmaceuticals Moat Score Related Terms

FRA:RI2 vs CADL, IMMX, AURA: Moat Score Comparison

For the Biotechnology subindustry, Rigel Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rigel Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Moat Score falls into.


FRA:RI2
76GF Score
Rigel Pharmaceuticals Inc FRA:RI2
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Rigel Pharmaceuticals (FRA:RI2) has a Moat Score of 3 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Rigel Pharmaceuticals ranks #343 out of 1401 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Rigel Pharmaceuticals' Moat Score too high?
Rigel Pharmaceuticals' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Rigel Pharmaceuticals' value of 3 is 50% above this industry median. Based on the distribution chart, Rigel Pharmaceuticals ranks #343 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rigel Pharmaceuticals has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Moat Score compare to CADL and IMMX?
According to the Biotechnology industry distribution chart, Rigel Pharmaceuticals ranks #343 out of 1401 companies for Moat Score. This places Rigel Pharmaceuticals in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Rigel Pharmaceuticals' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rigel Pharmaceuticals's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rigel Pharmaceuticals's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Rigel Pharmaceuticals (FRA:RI2) has a current Moat Score of 3. The stock's GF Value™ is €24.33, compared to a current price of €33.59 — trading 38.1% above its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Rigel Pharmaceuticals' overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current Moat Score is 3 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of €33.59 is trading 38.1% above its estimated GF Value™ of €24.33.

Key valuation signals for FRA:RI2:

  • Moat Score: 3
  • GF Value™: €24.33 vs. price of €33.59 (38.1% above fair value)
  • GF Score™: 76/100 with 7 warning signs
  • Industry Position: 50% above the Biotechnology median (#343 of 1401)

No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rigel Pharmaceuticals Business Description

Other Exchanges RIGL:USA
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
76GF Score

Get the complete analysis for FRA:RI2

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.59
Price
€24.33
GF Value